Profile and Antibiotic Pattern of Blood Stream Infections of Patients Receiving Hematopoietic Stem Cell Transplants in Southwest China
Qiang Zeng,Bing Xiang,Zhigang Liu
DOI: https://doi.org/10.2147/IDR.S358926
2022-04-22
Infection and Drug Resistance
Abstract:Qiang Zeng, Bing Xiang, Zhigang Liu Department of Hematology, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China Correspondence: Zhigang Liu, Email Background: Bloodstream infection (BSI) is a serious medical issue causing non-relapsed mortality in patients receiving hematopoietic stem cell transplantations (HSCT). Methods: The characteristics of all patients receiving HSCT (autologous and allogeneic HSCT) in our hospital from 2013 to 2019 were studied. Ratios, medians, and ranges were calculated to describe categorical variables. Chi-square tests were performed to compare the difference between ratios. Results: A total of 741 patients receiving 746 HSCT procedures—including 376 allogeneic, 370 autologous, and four of both types—were included in the study. The overall incidence of BSI in post-transplantation patients was 8.8% (N = 65). Gram-negative bacteria were the most common strains each year (33.3– 81.3%), and E. coli was the most frequently isolated (33.3%). Enterobacterales represented 64.9% of multidrug-resistant (MDR) bacteria, and the ratio of MDR rebounded from 25% to 100% within a year. A total of 27 patients died from BSI after HSCT, and the seven-day and 30-day death tolls were 12 and 18, respectively. MDR caused 63% of deaths among patients with BSI and the mortality rate caused by tigecycline-resistance was as high as 100%. Conclusion: Our results reveal the changing epidemiology of BSI and antibiotic resistance in patients receiving HSCT in Southwest China, as well as showing that MDR and tigecycline-resistant microorganisms should be given more attention. Thus, long-term routine microorganism epidemiological and resistance monitoring in patients undergoing HSCT should be a vital practice in future. Keywords: bloodstream infection, hematopoietic stem cell transplantations, multidrug-resistant bacteria Infection is one of the most common complications causing transplantation failure and non-relapse mortality (NRM) in hematological malignancy patients after hematopoietic stem cell transplants (HSCT). 1 Bloodstream infection (BSI) is a high risk and is related to incidence and NRM rates, with BSI rates ranging from 13% to 55.8%, and NRM ranging from 24% to 43.6%. 2–8 Therefore, an in-depth understanding of the characteristics of BSI in patients receiving HSCT is necessary. Since the 1960s, the major pathogen type implicated in BSI has shifted from gram-negative bacteria (GNB) to gram-positive bacteria (GPB) and back again. 6,9–11 This trend has continued into the 21st century, to the extent, that GNB has again become the main pathogen of BSI. 4,12,13 Furthermore, multidrug-resistant (MDR) bacteria and extensively drug-resistant (XDR) bacteria have become an increasing global concern, 14 representing significant challenges to the medical profession. The problem is more prominent in patients undergoing HSCT due to the extended use of antibiotic prophylaxis and broad-spectrum antibiotics. 4,15 According to available—but incomplete statistics—the quinolone resistance rate has increased to 86% in some countries, while the incidence of carbapenem resistance increases to 25% from the initial zero-resistance state in post-transplantation patients on average every year. 4,6,16,17 The overall resistance rate of tigecycline—one of the last possible treatment options of antibiotics—has not been reported in China or abroad to date. Understanding the resistance rate is important when choosing antibiotics, as trends in resistance profiles change annually and have a significant bearing on treatment outcomes. 12 To date, the characteristics of post-HSCT BSI have been retrospectively investigated in the United States and various European countries at different times, but data about BSI after HSCT in China is scarce, especially in Southwest China. Therefore, our study was designed to describe the frequency of BSI and antimicrobial susceptibility in patients receiving HSCT in our hospital from 2013 to 2019, with the aim of clarifying the epidemiology of BSI and the rates of resistance to antibiotics demonstrated after HSCT in Southwest China. The study was designed to analyze BSI in patients during HSCT retrospectively at West China Hospital from 2013 to 2019. All patients older than 14 who underwent HSCT were included. In our study, each year was analyzed as a separate period, and BSI data for different years were compared. Certain characteristics of all patients were noted, including demographics, underlying disease, transplant type, BSI episodes, infection sites, antimicrobial susceptibility, and survival. Incidence was calculated according to the positive rate of blood culture episodes per the -Abstract Truncated-
pharmacology & pharmacy,infectious diseases